Meeting
2012 ASCO Annual Meeting
The impact of interval cytoreduction and age in advanced-stage ovarian cancer: A GOG ancillary study.
Authors
Stuart M. Lichtman
Memorial Sloan-Kettering Cancer Center, New York, NY
Stuart M. Lichtman , James Java , John L. Lovecchio , Dennis Chi , William P. Tew , Michael A. Bookman , Andrew Menzin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5056)
DOI
10.1200/jco.2012.30.15_suppl.5056
Abstract #
5056
Poster Bd #
19H
Abstract Disclosures
Similar Posters
First Author: Elena Ioana Braicu
Poster
2023 ASCO Annual Meeting
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).
First Author: Yi Jiang
Poster
2022 ASCO Annual Meeting
Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial.
First Author: Jalid Sehouli
Poster
2021 ASCO Annual Meeting
Does aggressive surgery only benefit patients with less advanced ovarian cancer?
First Author: Shinichi Tate